Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
Tempus (NASDAQ: TEM) announced a multi-year collaboration with Genialis to develop RNA-based biomarker algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate and enhance their AI foundation model, which uses data from approximately 1 million RNA-sequencing samples.
Through this partnership, Genialis gains access to Tempus' analytics platform, Lens, providing development tools and de-identified patient records. In return, Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for commercialization within their xR platform.
The collaboration has already contributed to the launch of Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' real-world data, effectively stratifies patients into response likelihood groups.
Tempus (NASDAQ: TEM) ha annunciato una collaborazione pluriennale con Genialis per sviluppare algoritmi biomarker basati su RNA per il trattamento del cancro. Genialis utilizzerà il set di dati multimodale di Tempus per convalidare e migliorare il proprio modello fondato sull'AI, che utilizza dati provenienti da circa 1 milione di campioni di sequenziamento RNA.
Attraverso questa partnership, Genialis ottiene accesso alla piattaforma analitica di Tempus, Lens, che fornisce strumenti di sviluppo e dati di pazienti de-identificati. In cambio, Tempus riceve i diritti per valutare e potenzialmente licenziare gli algoritmi sviluppati da Genialis per la commercializzazione all'interno della loro piattaforma xR.
La collaborazione ha già contribuito al lancio di Genialis™krasID, il primo algoritmo commerciale che prevede la risposta del paziente alle terapie mirate a KRAS attraverso diversi tipi di cancro. Questo algoritmo, convalidato utilizzando i dati del mondo reale di Tempus, stratifica efficacemente i pazienti in gruppi di probabilità di risposta.
Tempus (NASDAQ: TEM) anunció una colaboración de varios años con Genialis para desarrollar algoritmos de biomarcadores basados en RNA para el tratamiento del cáncer. Genialis utilizará el conjunto de datos multimodal de Tempus para validar y mejorar su modelo fundamental de IA, que utiliza datos de aproximadamente 1 millón de muestras de secuenciación de RNA.
Mediante esta asociación, Genialis obtiene acceso a la plataforma analítica de Tempus, Lens, que proporciona herramientas de desarrollo y registros de pacientes desidentificados. A cambio, Tempus recibe derechos para evaluar y potencialmente licenciar los algoritmos desarrollados por Genialis para su comercialización dentro de su plataforma xR.
La colaboración ya ha contribuido al lanzamiento de Genialis™krasID, el primer algoritmo comercial que predice la respuesta del paciente a las terapias dirigidas a KRAS en diferentes tipos de cáncer. Este algoritmo, validado utilizando datos del mundo real de Tempus, estratifica eficazmente a los pacientes en grupos de probabilidad de respuesta.
템퍼스 (NASDAQ: TEM)는 제니알리스와 암 치료를 위한 RNA 기반 바이오마커 알고리즘 개발을 위한 다년간 협력을 발표했습니다. 제니알리스는 약 100만 개의 RNA 시퀀싱 샘플 데이터를 이용해 템퍼스의 다중 모달 데이터 세트를 활용하여 AI 기초 모델을 검증하고 향상시키게 됩니다.
이 파트너십을 통해 제니알리스는 템퍼스의 분석 플랫폼인 렌즈에 접근하여 개발 도구와 비식별화된 환자 기록을 제공합니다. 그 대가로 템퍼스는 제니알리스가 개발한 알고리즘을 상업화하기 위해 평가하고 잠재적으로 라이선스할 권리를 받습니다.
이 협력은 이미 제니알리스™krasID의 출시에도 기여했습니다. 이는 다양한 암 유형에 걸쳐 KRAS 표적 치료에 대한 환자의 반응을 예측하는 첫 상업 알고리즘입니다. 이 알고리즘은 템퍼스의 실제 데이터로 검증되어 환자들을 반응 가능성 그룹으로 효과적으로 분류합니다.
Tempus (NASDAQ: TEM) a annoncé une collaboration pluriannuelle avec Genialis pour développer des algorithmes de biomarqueurs basés sur l'ARN pour le traitement du cancer. Genialis utilisera le jeu de données multimodal de Tempus pour valider et améliorer son modèle fondamental d'IA, qui utilise des données provenant d'environ 1 million d'échantillons de séquençage d'ARN.
Grâce à ce partenariat, Genialis a accès à la plateforme analytique de Tempus, Lens, qui fournit des outils de développement et des dossiers patients anonymisés. En retour, Tempus reçoit le droit d'évaluer et de potentiellement accorder une licence sur les algorithmes développés par Genialis pour la commercialisation au sein de sa plateforme xR.
La collaboration a déjà contribué au lancement de Genialis™krasID, le premier algorithme commercial prédisant la réponse des patients aux thérapies ciblées KRAS à travers différents types de cancer. Cet algorithme, validé à l'aide des données du monde réel de Tempus, stratifie efficacement les patients en groupes de probabilité de réponse.
Tempus (NASDAQ: TEM) gab eine mehrjährige Zusammenarbeit mit Genialis bekannt, um RNA-basierte Biomarker-Algorithmen für die Krebsbehandlung zu entwickeln. Genialis wird die multimodalen Datensätze von Tempus nutzen, um ihr KI-Grundlagenmodell zu validieren und zu verbessern, das Daten aus etwa 1 Million RNA-Sequenzierungsproben verwendet.
Durch diese Partnerschaft erhält Genialis Zugang zur Analyseplattform von Tempus, Lens, die Entwicklungstools und anonymisierte Patientenakten bereitstellt. Im Gegenzug erhält Tempus das Recht, die von Genialis entwickelten Algorithmen zu bewerten und möglicherweise für die Commercialisierung innerhalb ihrer xR-Plattform zu lizenzieren.
Die Zusammenarbeit hat bereits zur Einführung von Genialis™krasID beigetragen, dem ersten kommerziellen Algorithmus, der die Patientenreaktion auf KRAS-zielgerichtete Therapien über verschiedene Krebsarten hinweg vorhersagt. Dieser Algorithmus, der mit realen Daten von Tempus validiert wurde, stratifiziert Patienten effektiv in Gruppen mit verschiedenen Wahrscheinlichkeiten für eine Reaktion.
- Strategic access to Tempus' extensive multimodal dataset for algorithm validation
- Potential revenue stream from licensing Genialis-developed algorithms
- Successful launch of first commercial product (krasID) using the partnership's resources
- None.
Insights
This strategic collaboration marks a pivotal development in precision oncology. The partnership leverages Tempus' vast multimodal dataset and Genialis' RNA-based AI foundation model trained on ~1 million RNA-sequencing samples - a scale that's unprecedented in the field.
The first commercial output, Genialis™ krasID, represents a breakthrough in KRAS-targeted therapy patient selection. KRAS mutations are present in approximately
For Tempus, this deal provides potential revenue streams through algorithm licensing and strengthens its xR platform's competitive position in the precision medicine market. The collaboration also validates Tempus' data asset value, potentially attracting similar high-value partnerships in the future.
The technological significance of this collaboration lies in its novel approach to biomarker development. Genialis' Large Molecular Model (LMM) represents a sophisticated application of foundation models in healthcare - similar to how GPT works for language, but specialized for RNA data analysis.
The validation against Tempus' real-world data is important - it addresses a common challenge in AI healthcare applications where models trained on research data often underperform in clinical settings. This real-world validation significantly increases the commercial viability of the developed algorithms.
The integration with Tempus' Lens platform provides Genialis with both data access and development tools, potentially accelerating the biomarker development pipeline. This could lead to faster market entry for new clinical algorithms, providing Tempus with a competitive edge in the growing precision medicine market.
Clinical care for cancer patients is hindered by insufficient biomarkers that fail to accurately predict patient response to treatment. To address this, Genialis has developed an AI foundation model using data from ~1 million RNA-sequencing samples representing globally diverse patients. This large molecular model (LMM), dubbed the Genialis TM Supermodel, yields accurate and information-rich biomarker algorithms to help biopharma improve therapeutic development. Validating Genialis’ LMM using Tempus real-world multi-modal data is essential to demonstrate the clinical utility and broad applicability of these biomarkers in drug development and clinical practice. As part of the collaboration, Genialis can now leverage Tempus’ analytics platform, Lens, which provides a development platform accessing de-identified multimodal patient records and a suite of tools to validate signatures to accelerate the company’s efforts to bring its clinical algorithms to market. In return, Tempus gains the right to evaluate and potentially license Genialis-developed algorithms for commercialization as a component of the xR platform.
Tempus multimodal dataset has already proved pivotal in the launch of Genialis™krasID, the first commercially available algorithm that stratifies patients who benefit from KRAS inhibition. Presented at the 6th Annual Targeting-RAS Drug Development Summit in September 2024, Genialis krasID uniquely predicts patient response to KRAS-targeted therapies across cancer types and driver mutations. Independently validated using Tempus’ real-world data, Genialis krasID stratifies patients into high and low likelihood response groups that have been evaluated in real-world studies1,2.
“We look forward to working with Genialis and demonstrating new ways in which our data can be applied to further a new kind of research, one that embraces the power that RNA-based biomarkers can have on the future of cancer care,” said Kate Sasser, Ph.D., Chief Scientific Officer at Tempus. “Multimodal algorithms, including RNA signatures, are demonstrating rapid advancement in clinical utility for personalized treatment decisions, and we are excited to partner with Genialis to fuel this data-driven precision medicine future with our xR assay and vast multimodal dataset.”
“Biomarkers have the potential to transform how cancer is diagnosed and treated, but today’s standard of care leaves a lot to be desired in terms of accuracy, information richness, and patient reach,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “With this strategic agreement with Tempus, Genialis will have access to an unparalleled data resource to validate our cutting-edge patient classifiers.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of the collaboration with Genialis in developing biomarker algorithms, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
About Genialis
Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit www.genialis.com
1berna, et al. (2024). Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy. Presented at the American Association for Cancer Research (AACR) Annual Meeting. Retrieved from https://www.genialis.com/2024/04/09/genialis-krasid-biology-driven-machine-learning-to-personalize-kras-inhibitor-therapy/
2berna, et al. (2024). krasID at RAS Drug Development Summit. Poster presented at the RAS Drug Development Summit, American Association for Cancer Research (AACR). Retrieved from https://www.genialis.com/2024/09/25/genialis-krasid-biology-driven-machine-learning-to-personalize-kras-inhibitor-therapy-2/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108867515/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What is the purpose of the Tempus-Genialis collaboration for TEM stock?
How will the Genialis partnership affect Tempus (TEM) product offerings?
What is the first commercial product developed through the TEM-Genialis collaboration?
What access does Genialis receive to Tempus (TEM) resources in this partnership?
